Condition
Castrate Resistance Prostate Cancer
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Early P 1 (1)
P 2 (1)
Trial Status
Recruiting1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
NCT06927635Phase 2RecruitingPrimary
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
NCT04113005Early Phase 1UnknownPrimary
Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer
Showing all 2 trials